> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Precigen Is Owed $96.5 Million On 127-Day Payment Terms, Nearly All Of It By One Wholesaler
- URL: https://www.bullished.co/precigen-is-owed-96-5-million-on-127-day-payment-terms-nearly-all-of-it-by-one-wholesaler-9bec5840/
- Published: 2026-11-04T22:06:45.000Z
- Updated: 2026-11-04T22:06:45.000Z
- Description: Receivables jumped from $3.9 million at year-end, and nine-month operating cash flow is still negative $49.8 million despite profit.
- Author: Matteo Parrino
- Tags: SEC Filings, PGEN, Industry: Healthcare

Trade receivables at Precigen, maker of the rare-disease therapy Papzimeos, reached [$96.5 million](https://www.sec.gov/Archives/edgar/data/0001356090/000135609026000040/pgen-20260930.htm?ref=bullished.co) at September 30, against $3.9 million at December 31, 2025, the company's 10-Q filed Wednesday shows. About 99% of the receivables sit with a single wholesaler, and the company gives customers 127 days to pay.

## Profit on paper, cash outflow in practice

Precigen reported net income of $47.9 million for the first nine months, yet operating activities consumed $49.8 million of cash, against $64.4 million used a year earlier. The company says changes in operating assets and liabilities used $112.2 million, driven mainly by growth in receivables and inventory as Papzimeos sales ramped, and ties the receivables build to the 127-day terms.

At six months, operating cash flow stood at negative $61.6 million, according to the [prior filing](https://www.sec.gov/Archives/edgar/data/0001356090/000135609026000030/pgen-20260630.htm?ref=bullished.co). Management reports positive operating cash flow of $11.9 million for the third quarter alone.

Third-quarter revenue was $74.1 million, including $72.9 million of net Papzimeos product revenue, against $2.9 million total a year earlier. Operating income was $38.7 million for the quarter.

## One wholesaler holds 99% of the receivables

The company sells all Papzimeos product through a large commercial pharmaceutical wholesaler that it says holds an investment-grade credit rating. That wholesaler accounted for about 99% of receivables at September 30, up from about 89% at year-end.

Precigen, which develops gene and cell therapies, won full FDA approval for Papzimeos in August 2025 for adults with recurrent respiratory papillomatosis, a rare disease caused by chronic HPV 6 or HPV 11 infection. It estimates about 27,000 adult patients in the United States live with the disease.

## Cash cushion and a rival drug

Cash, cash equivalents and investments totaled $51.0 million at September 30, up from $38.7 million at June 30, while long-term debt carried at $94.3 million has $100 million of principal outstanding. Management says cash plus anticipated receivable collections will fund operations for at least one year.

With its cheaper pre-launch stock now essentially gone, Precigen expects Papzimeos cost of products to climb relative to revenue. In September, the FDA granted platform technology designation to its AdenoVerse platform.

Yahoo Finance [reported](https://finance.yahoo.com/markets/stocks/articles/pgen-stock-craters-27-hours-222420610.html?ref=bullished.co) that the FDA's approval of Inovio's rival drug for the disease sent Precigen shares down 27% after hours. The company's market value stood at $1.9 billion.

Precigen's own filing says its path to sustained profitability depends on continued successful commercialization of Papzimeos, and its stated plan to finance cash needs starts with collecting those receivables.

### Sources

- [10-Q Filing — Precigen (PGEN)](https://www.sec.gov/Archives/edgar/data/0001356090/000135609026000040/pgen-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Precigen (PGEN), Q2 FY2026 filed 2026-08-04 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001356090/000135609026000030/pgen-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?](https://finance.yahoo.com/healthcare/articles/precigen-gears-report-q3-earnings-144200574.html?ref=bullished.co) — Yahoo Finance
- [Can Precigen (PGEN) Justify Its Valuation As Inovio Approval Tests Papzimeos?](https://sg.finance.yahoo.com/news/precigen-pgen-justify-valuation-inovio-051152711.html?ref=bullished.co) — Yahoo Finance
- [PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval](https://finance.yahoo.com/markets/stocks/articles/pgen-stock-craters-27-hours-222420610.html?ref=bullished.co) — Yahoo Finance
- [Watching This Rare-Disease Biotech as Hyperscalers Lead Post-Election Market](https://pro.thestreet.com/market-commentary/watching-this-rare-disease-biotech-as-hyperscalers-lead-post-election-market?ref=bullished.co) — pro.thestreet.com
- [This Biotech Got Hit on a Competitor’s Good News. Here’s Why I’m Adding](https://pro.thestreet.com/trade-ideas/this-biotech-got-hit-on-a-competitors-good-news-heres-why-im-adding?ref=bullished.co) — pro.thestreet.com